ACQUISITION (Details - purchase price allocation) - USD ($)		3 Months Ended	12 Months Ended
	Jun. 16, 2023	Aug. 31, 2023	Aug. 31, 2023	Aug. 31, 2022	Aug. 31, 2021
Business Acquisition [Line Items]
Base merger consideration			$ 8,223,000	$ 0	$ 0
Fair value of earnout			4,100,000
Bonus compensation to Immunetrics staff	$ (1,586,000)	$ 1,600,000
Goodwill		19,099,000	19,099,000	12,921,000	12,921,000
Immunetrics
Business Acquisition [Line Items]
Base merger consideration	12,000,000
Payments to acquire businesses, gross	13,705,083
Fair value of earnout	4,100,000
Cash on hand	1,247,000
Adjustment to purchase price for closing indebtedness	(122,000)
Net working capital adjustment	(377,000)
D&O Tail	(7,000)
Total purchase price	15,255,000
Cash	1,132,000
Accounts receivable	511,000
Security deposit	12,000
ROU asset	227,000
Deferred tax assets	799,000
Finite-lived intangible assets acquired	4,890,000
Assets acquired	9,371,000
Lease liability	227,000
Selling shareholders' D&O tail responsibility	7,000
Deferred revenue	60,000
Business combination, liabilities assumed	294,000
Fair value of identifiable assets acquired and liabilities assumed	9,077,000
Goodwill	6,178,000	$ 6,178,000	$ 6,178,000	$ 0	$ 0
Immunetrics | Trade names
Business Acquisition [Line Items]
Indefinite-lived intangible assets acquired	1,800,000
Immunetrics | Customer relationships
Business Acquisition [Line Items]
Finite-lived intangible assets acquired	3,780,000
Immunetrics | Developed Tech
Business Acquisition [Line Items]
Finite-lived intangible assets acquired	1,080,000
Immunetrics | Covenants not to compete
Business Acquisition [Line Items]
Finite-lived intangible assets acquired	$ 30,000